Clinical Trials
48 trialsNCT07205315 2026-05-27
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
Grit Biotechnology
Phase EARLY_PHASE1 Recruiting
NCT05838599 2026-05-01
Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides
Northwestern University
Phase EARLY_PHASE1 Recruiting
NCT06735690 2026-04-27
Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia
City of Hope Medical Center
Phase EARLY_PHASE1 Recruiting
NCT07548697 2026-04-23
A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1 Recruiting
NCT03422731 2026-04-15
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
City of Hope Medical Center
Phase EARLY_PHASE1 Recruiting
NCT07376642 2026-03-30
A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Suzhou Immunofoco Biotechnology Co., Ltd
Phase EARLY_PHASE1 Recruiting
NCT05294367 2026-03-16
Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma
Mayo Clinic
Phase EARLY_PHASE1 Recruiting
NCT07428707 2026-03-13
Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
National Institutes of Health Clinical Center (CC)
Phase EARLY_PHASE1 Recruiting
NCT07429461 2026-02-24
Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT04512716 2026-02-17
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT05093335 2026-02-05
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT05800405 2026-02-04
Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
City of Hope Medical Center
Phase EARLY_PHASE1 Recruiting
NCT05921253 2026-01-26
OU-SCC-NCAN
University of Oklahoma
Phase EARLY_PHASE1 Recruiting
NCT07349849 2026-01-20
Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies
Xinqiao Hospital of Chongqing
Phase EARLY_PHASE1 Recruiting
NCT06765876 2026-01-12
UHKT-CAR123-01
Institute of Hematology and Blood Transfusion, Czech Republic
Phase EARLY_PHASE1 Recruiting
NCT06514768 2026-01-06
JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase EARLY_PHASE1 Recruiting
NCT07312630 2025-12-31
Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Recruiting
NCT07162012 2025-12-02
Anti-EBV TCR-T
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase EARLY_PHASE1 Recruiting
NCT06398457 2025-09-26
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Recruiting
NCT06120166 2025-09-19
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT07101705 2025-09-09
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1 Recruiting
NCT06446128 2025-08-21
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)
Shanghai Cell Therapy Group Co.,Ltd
Phase EARLY_PHASE1 Recruiting
NCT03719105 2025-08-08
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
New York Medical College
Phase EARLY_PHASE1 Recruiting
NCT06636175 2025-07-31
64Cu-LLP2A for Imaging Hematologic Malignancies
Washington University School of Medicine
Phase EARLY_PHASE1 Recruiting
NCT06976437 2025-07-10
A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
Affiliated Hospital of Jiangsu University
Phase EARLY_PHASE1 Recruiting
NCT04139304 2025-06-29
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
AIDS Malignancy Consortium
Phase EARLY_PHASE1 Recruiting
NCT06092047 2025-05-16
UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Recruiting
NCT06532630 2025-02-28
Anti-CD19-CAR-T Cells in Subjects With Relapsed/Refractory B Cell Malignancies
Shanghai First Song Biotechnology Co., LTD
Phase EARLY_PHASE1 Recruiting
NCT06793241 2025-01-27
Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT06307600 2025-01-23
The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia
Anhui Provincial Hospital
Phase EARLY_PHASE1 Recruiting
NCT05651178 2025-01-07
Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients
Hrain Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Recruiting
NCT06756321 2025-01-03
A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
Affiliated Hospital of Nantong University
Phase EARLY_PHASE1 Recruiting
NCT06716164 2024-12-04
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT06696833 2024-11-20
Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University
Phase EARLY_PHASE1 Recruiting
NCT06693973 2024-11-19
An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1 Recruiting
NCT06659653 2024-10-26
Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.
The First People's Hospital of Jingzhou
Phase EARLY_PHASE1 Recruiting
NCT06643221 2024-10-16
Allo-X
University of Arizona
Phase EARLY_PHASE1 Recruiting
NCT06633341 2024-10-09
Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT06633354 2024-10-09
Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT06532643 2024-09-19
Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma
Shanghai First Song Biotechnology Co., LTD
Phase EARLY_PHASE1 Recruiting
NCT05501899 2024-08-21
Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia
Children's Hospital of Orange County
Phase EARLY_PHASE1 Recruiting
NCT06224049 2024-03-12
GI-hNeoT-01
BGI, China
Phase EARLY_PHASE1 Recruiting
NCT04662294 2021-11-04
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT04227015 2020-12-28
A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT04603872 2020-10-28
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT04532203 2020-10-26
A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT04532281 2020-10-26
A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT04532268 2020-08-31
A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL
Zhejiang University
Phase EARLY_PHASE1 Recruiting